Home

Thomas Bures

CIK 1787029 · Chief Accounting Officer · last filed 2026-08-18

Thomas Bures is a Chief Accounting Officer who has filed 8 SEC Form 4 insider transactions across 3 companies since 2020. The most recent filing, for BRKR, was dated Aug 18, 2026. Across all open-market trades the lifetime net is +$23.7K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.7M across reported positions. 5 SEC filings were submitted jointly with BRUKER CORP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.66M

Companies

3

Total Filings

8

Lifetime Open-Market Net

$23.7K

Filer Profile

Reported Address
C/O PIERIS PHARMACEUTICALS, INC.
255 STATE STREET, 9TH FLOOR
BOSTON, MA 02109
Related Filers
BRUKER CORP — 5 joint filings, latest 2026-08-18
PALVELLA THERAPEUTICS, INC. — 5 joint filings, latest 2023-02-28
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BRKR Chief Accounting Officer 7,233 $53.43 $386.5K $23.7K 3 2026-08-18
BRKRP Chief Accounting Officer 3,198 $399.57 $1.28M $0 1 2026-02-18
PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Chief Financial Officer — $13.60 — $0 4 2023-02-28

Recent Filings

8 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-18 BRKR Grant (A) +4,035 $0 EDGAR
2026-02-18 BRKRP Tax (F) −274 -$10.0K EDGAR
2025-03-11 BRKR Buy (P) +500 $23.7K EDGAR
2025-02-19 BRKR Grant (A) +2,972 $0 EDGAR
2023-02-28 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2022-02-24 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2021-03-08 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
2020-03-02 PALVELLA THERAPEUTICS, INC. (PIRS) Delisted Grant (A) — $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.